# Anti-VEGF therapy - a new hope in AMD treatment

## TL;DR

Anti-VEGF therapy is a promising treatment for AMD by targeting blood vessel growth in the eye.

## Contribution

This paper highlights the role of anti-VEGF therapy in treating AMD by inhibiting choroidal neovascularization.

## Key findings

- VEGF inhibition has become a principal target in neovascular AMD treatment.
- Intravitreal anti-VEGF agents help achieve anatomical restoration and better visual outcomes.
- Sustained dosing is necessary for effective anti-VEGF therapy in AMD.

## Abstract

Choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) represents a significant global cause of visual impairment. Contemporary therapeutic approaches for neovascular AMD focus on inducing regression of CNV by inhibiting critical growth factors involved in angiogenesis. For nearly two decades, vascular endothelial growth factor (VEGF) has been the principal therapeutic target, with multiple intravitreally administered agents developed to achieve anatomical restoration and improved visual outcomes through sustained dosing.